Richard L. Schilsky, MD, on Highlights of the 2016 ASCO Annual Meeting

2016 ASCO Annual Meeting

Richard L. Schilsky, MD, ASCO’s Chief Medical Officer, discusses the key presentations at this year’s conference.

A. Oliver Sartor, MD, and Celestia S. Higano, MD, on Findings of the FIRSTANA Trial in Prostate Cancer

A. Oliver Sartor, MD, of Tulane University, and Celestia S. Higano, MD, of the University of Washington, discuss findings from this phase III study on cabazitaxel vs docetaxel in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (Abstract 5006).

Issues in Oncology

Patricia J. Goldsmith on Patient Access and Engagement: Results of the CancerCare Report

Patricia J. Goldsmith, Chief Executive Officer of CancerCare, which provides free, professional support services to anyone affected by cancer, discusses findings from six distinct surveys with input from more than 3,000 individuals at varying stages of their cancer experience.

Issues in Oncology

Eric Roeland, MD, and Timothy E. Quill, MD, on the Debate Over Physician-Assisted Death

Eric Roeland, MD, of the University of California, San Diego, and Timothy E. Quill, MD, of the University of Rochester Medical Center, discuss the debate on whether physician-assisted death should be a legally available option at the end of life when neither palliative nor hospice care is satisfactory.

Gynecologic Cancers

Helen MacKay, MD, on Epithelial Ovarian Cancer: Results From the OV21/PETROC Trial

Helen MacKay, MD, of the Sunnybrook Odette Cancer Centre, discusses findings from this phase II study of intraperitoneal vs intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in patients with epithelial ovarian cancer (Abstract LBA5503).

Multiple Myeloma

Michele Cavo, MD, on Multiple Myeloma: Results From a European Myeloma Network Trial (Italian Language Version)

Michele Cavo, MD, of the Seràgnoli Institute of Hematology, Bologna University School of Medicine, discusses in Italian results from this phase III study of upfront autologous stem cell transplantation vs novel agent-based therapy for multiple myeloma (Abstract 8000).

To see the English language version of this video, please click here.

Dec

Today In Oncology

Richard L. Schilsky, MD, on Highlights of the 2016 ASCO Annual Meeting

Related Videos

A. Oliver Sartor, MD, and Celestia S. Higano, MD, on Findings of the FIRSTANA Trial in Prostate Cancer

Patricia J. Goldsmith on Patient Access and Engagement: Results of the CancerCare Report

Eric Roeland, MD, and Timothy E. Quill, MD, on the Debate Over Physician-Assisted Death

Helen MacKay, MD, on Epithelial Ovarian Cancer: Results From the OV21/PETROC Trial

Michele Cavo, MD, on Multiple Myeloma: Results From a European Myeloma Network Trial (Italian Language Version)

Adding Tucatinib to First-Line Maintenance Therapy Delays Disease Progression in HER2-Positive Metastatic Breast Cancer

Mobile Health Intervention Offers Tailored Support for Adolescent and Young Adult Breast Cancer Survivors

Can Multimodal AI Models Predict Distant Recurrence Risk in Patients With Early Breast Cancer

Doublet Therapy Yields Higher Response Rates and Fewer Complications Than Standard Induction in AML

Ianalumab Plus Eltrombopag Extends Time to Treatment Failure in ITP